ArticleFrontiers in public health2022

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.

Ying-Tao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.